Abstract: The present disclosure relates to antibodies that selectively bind to CD3 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.

Abstract: A computer system is configured to receiving a data set from a data provider and automatically save the data set in a quarantine database where copying, moving, and sharing of the data set are restricted until the data set is released by a data provider. The data set is parsed to find and mark portions with potentially sensitive information. At least those parts are reviewed by a data governor, who can confirm, add, edit, or remove markers. Those parts can be visually indicated to the data governor, along with a preview of, metadata about, and analysis of the data set. After reviewing at least the automatically marked portions, the data governor can release the data set to a non-quarantine database where another user can use the data set. The user is restricted from accessing the quarantine database.

Abstract: A system and method can provide charter-based access to resources using an object model. Charters are defined by an administrator to have certain markings, each marking indicating a control (e.g., permission, credential, qualification, constraint, requirement, etc.) that regulates work under the charter. Users are also associated with markings. A user starts a session to access the system and is authenticated. The system determines charters having markings that the user has, and these charters are provided to the user to select from. Selecting a charter allows the user access to resources associated with the charter, under the controls indicated by the markings. Charters, controls, qualifications, resources, authorizations and links between them can be implemented using an object model. Markings can control session parameters (e.g.

Abstract: Compositions, methods, and kits are provided for diagnosing hepatocellular carcinoma in patients. In particular, methylated cell-free DNA biomarkers and methods of using them to determine if a patient has hepatocellular carcinoma are provided. Additionally, the methylated cell-free DNA biomarkers can be used to distinguish between patients with a chronic liver disease such as cirrhosis who do not have hepatocellular carcinoma and those patients with a chronic liver disease who have hepatocellular carcinoma. The identified biomarkers can be used alone or in combination with one or more additional biomarkers or relevant clinical parameters in prognosis, diagnosis, therapy selection, or monitoring treatment of hepatocellular carcinoma.

Abstract: A system and method can provide charter-based access to resources using an object model. Charters are defined by an administrator to have certain markings, each marking indicating a control (e.g., permission, credential, qualification, constraint, requirement, etc.) that regulates work under the charter. Users are also associated with markings. A user starts a session to access the system and is authenticated. The system determines charters having markings that the user has, and these charters are provided to the user to select from. Selecting a charter allows the user access to resources associated with the charter, under the controls indicated by the markings. Charters, controls, qualifications, resources, authorizations and links between them can be implemented using an object model. Markings can control session parameters (e.g.

Abstract: System and method for k-anonymization with a target k-value according to certain embodiments. For example, a method includes: receiving an input dataset; receiving a k-value, the k-value being a positive integer; receiving one or more quasi-identifiers corresponding to one or more data fields in the input dataset; receiving a data suppression strategy including one or more transformation steps, at least one transformation step of the one or more transformation steps associated with at least one quasi-identifier of one or more one or more quasi-identifiers; and applying the one or more transformation steps to the input dataset to generate a suppressed dataset including at least one suppressed data field corresponding to the at least one data field; checking an anonymity value of each data record of a plurality of data records in the suppressed dataset; selecting a subset of the suppressed dataset from the suppressed dataset.

Abstract: An isolated cancer-targeting peptide that includes at least two copies of the amino acid sequence PFLP (SEQ ID NO: 1) or PFLF (SEQ ID NO: 2). Also disclosed is a pharmaceutical composition for treating cancer. The composition contains the isolated cancer-targeting peptide and an anti-cancer agent. Further disclosed is a bispecific anti-cancer antibody that includes the isolated cancer-targeting peptide and an antigen-binding peptide that stimulates T cell activity. Methods are provided for treating cancer by administering the pharmaceutical composition or the bispecific anti-cancer antibody. Further provided is a method for diagnosing cancer by administering a radionuclide-labeled cancer-targeting peptide to an individual and imaging a location of the radionuclide.

Abstract: Systems and methods are provided for processing an input dataset or running an inference. The systems and methods may be configured to accept an input dataset, access one or more predefined logic plugins for processing the input dataset, process the input dataset based at least in part on a first predefined logic plugin, and generate the one or more outputs based at least in part of the processing of the input dataset. The one or more outputs may have a different format than a format of the input dataset.

Abstract: A computer system is configured to receiving a data set from a data provider and automatically save the data set in a quarantine database where copying, moving, and sharing of the data set are restricted until the data set is released by a data provider. The data set is parsed to find and mark portions with potentially sensitive information. At least those parts are reviewed by a data governor, who can confirm, add, edit, or remove markers. Those parts can be visually indicated to the data governor, along with a preview of, metadata about, and analysis of the data set. After reviewing at least the automatically marked portions, the data governor can release the data set to a non-quarantine database where another user can use the data set. The user is restricted from accessing the quarantine database.

Abstract: An isolated cancer-targeting peptide that includes at least two copies of the amino acid sequence PFLP (SEQ ID NO: 1) or PFLF (SEQ ID NO: 2). Also disclosed is a pharmaceutical composition for treating cancer. The composition contains the isolated cancer-targeting peptide and an anti-cancer agent. Further disclosed is a bispecific anti-cancer antibody that includes the isolated cancer-targeting peptide and an antigen-binding peptide that stimulates T cell activity. Methods are provided for treating cancer by administering the pharmaceutical composition or the bispecific anti-cancer antibody. Further provided is a method for diagnosing cancer by administering a radionuclide-labeled cancer-targeting peptide to an individual and imaging a location of the radionuclide.

Abstract: A computer system is configured to receiving a data set from a data provider and automatically save the data set in a quarantine database where copying, moving, and sharing of the data set are restricted until the data set is released by a data provider. The data set is parsed to find and mark portions with potentially sensitive information. At least those parts are reviewed by a data governor, who can confirm, add, edit, or remove markers. Those parts can be visually indicated to the data governor, along with a preview of, metadata about, and analysis of the data set. After reviewing at least the automatically marked portions, the data governor can release the data set to a non-quarantine database where another user can use the data set. The user is restricted from accessing the quarantine database.

Abstract: The present invention provides monoclonal antibodies or the antigen-binding portion thereof, that bind to a feto-embryonic dedifferentiated antigen, such as Leucine-rich Repeat Neuronal Protein 1 (LRRN1), a surface glycoprotein that is expressed abundantly on the surface of human embryonic stem cells prior to differentiation into embryoid bodies. Also disclosed herein are the uses of the novel LRRN1 antibodies.

Abstract: A system and method can provide charter-based access to resources using an object model. Charters are defined by an administrator to have certain markings, each marking indicating a control (e.g., permission, credential, qualification, constraint, requirement, etc.) that regulates work under the charter. Users are also associated with markings. A user starts a session to access the system and is authenticated. The system determines charters having markings that the user has, and these charters are provided to the user to select from. Selecting a charter allows the user access to resources associated with the charter, under the controls indicated by the markings. Charters, controls, qualifications, resources, authorizations and links between them can be implemented using an object model. Markings can control session parameters (e.g.

Abstract: A container comprises a container body, wherein a side face of the container body is provided with a container door, wherein the container door is engaged with a corner column on the container body and is fixed to the corner column via a hinge and is connected to a J-shaped strip column arranged on an outer side of the corner column. The corner column is connected to the J-shaped strip column via a corner block arranged on an end portion thereof, wherein the corner block, the corner column and the J-shaped strip column define a long strip-shaped space, the long strip-shaped space being provided with a management module. The management module comprises a radio positioning/communication system.

Abstract: Kits for detecting cancer, including an agent for measuring LRRN1 antibody and a label indicating that the reagent for measuring LRRN1 antibody is for detecting cancer are disclosed. Methods for detecting cancer in a subject, including the steps of measuring the level of LRRN1 antibody, wherein a higher LRRN1 antibody level in the subject compare to a control sample, indicates the presence of cancer, are also provided.

Abstract: The present invention provides methods of inhibiting or reducing the growth of cancer cells in a subject, by administering a therapeutic effective amount of Puf-A inhibitor, whereby the symptoms and signs of cancer in the subject are reduced. Also provided are polynucleotides and vectors encoding the shRNAs which target Puf-A expression, which are useful for the treatment of cancer.

Abstract: The present invention provides methods of inhibiting or reducing the growth of cancer cells in a subject, by administering a therapeutic effective amount of Puf-A inhibitor, whereby the symptoms and signs of cancer in the subject are reduced. Also provided are polynucleotides and vectors encoding the shRNAs which target Puf-A expression, which are useful for the treatment of cancer.

Abstract: Methods and compositions for treating retinal diseases comprising therapeutic amounts of a compound selected from a normal Puf-A gene product, an active polypeptide fragment thereof, an analog thereof or a peptidomimetic thereof. Vectors, including AAV vectors comprising the therapeutic compound are provided. Puf-A compositions suitable for subretinal, intravitreal, topical, subconjunctival, retrobulbar, periocular, suprachoroidal, or intraocular administration are provided. Methods for screening siRNA, RNAi and shRNA, small molecules and monoclonal antibodies that inhibit Puf-A target activity and reduce apoptosis are provided.

Abstract: Methods are disclosed which are useful in increasing maturation of dendritic cells from CD14+ mononuclear cells, by contact with a composition comprising a fucose-containing glycoprotein fraction from Ganoderma lucidum. The extract can also be used for increasing production of a cytokine or a chemokine in a dendritic cell or CD19+ B cell. In addition, a fucose-containing glycoprotein fraction from Ganoderma lucidum can be administered to a subject identified as needing increased immunoglobulin, cytokine, or chemokine production.

Abstract: Methods and compositions for treating retinal diseases comprising therapeutic amounts of a compound selected from a normal Puf-A gene product, an active polypeptide fragment thereof, an analog thereof or a peptidomimetic thereof. Vectors, including AAV vectors comprising the therapeutic compound are provided. Puf-A compositions suitable for subretinal, intravitreal, topical, subconjunctival, retrobulbar, periocular, suprachoroidal, or intraocular administration are provided. Methods for screening siRNA, RNAi and shRNA, small molecules and monoclonal antibodies that inhibit Puf-A target activity and reduce apoptosis are provided.